Symbols / CDT $0.49 +7.30%
CDT Chart
About
CDT Equity Inc., a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility. It has strategic services agreement with formulation development CDMO Agility Life Sciences to develop new solid oral-dosage form products. The company was formerly known as Conduit Pharmaceuticals Inc. and changed its name to CDT Equity Inc. in August 2025. The company was founded in 2019 and is based in Naples, Florida.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 1.79M |
| Enterprise Value | -1.17M | Income | -20.30M | Sales | — |
| Book/sh | 3.35 | Cash/sh | 2.35 | Dividend Yield | — |
| Payout | 0.00% | Employees | 6 | IPO | — |
| P/E | — | Forward P/E | — | PEG | — |
| P/S | — | P/B | 0.15 | P/C | — |
| EV/EBITDA | 0.07 | EV/Sales | — | Quick Ratio | 0.99 |
| Current Ratio | 1.66 | Debt/Eq | 43.83 | LT Debt/Eq | — |
| EPS (ttm) | -179.34 | EPS next Y | — | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-12 15:00 | ROA | -206.95% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 3.66M |
| Shs Float | 1.45M | Short Float | 4.88% | Short Ratio | 0.13 |
| Short Interest | — | 52W High | 168.00 | 52W Low | 0.44 |
| Beta | 1.81 | Avg Volume | 685.85K | Volume | 66.55K |
| Target Price | — | Recom | None | Prev Close | $0.46 |
| Price | $0.49 | Change | 7.30% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
—
Mean price target
2. Current target
$0.49
Latest analyst target
3. DCF / Fair value
$-81.28
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.49
Low
—
High
—
Mean
—
News
RSS: Latest CDT news- AI lets CDT Equity assess 3,000 diseases in hours, CEO says - Stock Titan Wed, 18 Mar 2026 12
- Cdt Equity stockholders approve all proposals at special meeting, positioning the company for next phase of growth - marketscreener.com Wed, 18 Mar 2026 12
- CDT Equity Stockholders Approve All Proposals at Special Meeting, Positioning the Company for Next Phase of Growth - The Manila Times Wed, 18 Mar 2026 12
- CDT Stock Price, Quote & Chart | CDT EQUITY INC (NASDAQ:CDT) - ChartMill Wed, 11 Mar 2026 07
- CDT Equity Announces 1-for-8 Reverse Stock Split - Nasdaq hu, 09 Oct 2025 07
- CDT Equity Expands Financing Through New Convertible Note - The Globe and Mail ue, 10 Mar 2026 20
- CDT Equity stock tumbles after $115M Sarborg stake deal - Investing.com Fri, 20 Feb 2026 08
- Why Did CDT Environmental Tech (CDTG) Stock Pop 42% After Hours - Sahm Fri, 06 Mar 2026 09
- CDT Equity Inc. Acknowledges Sarborg Limited's Expansion of AI Signature Agent Platform into Bacteria and Agrochemicals - Quiver Quantitative ue, 24 Feb 2026 08
- CDT Equity to Acquire 20% of Sarborg in Stock, Pre-Funded Warrants and $8 Million Cash - TradingView ue, 24 Feb 2026 08
- CDT Stock Dips as Financial Challenges Mount Amid Market Shifts - timothysykes.com Fri, 20 Feb 2026 08
- How new solid-form patents could help drugs outlast patent cliffs - Stock Titan Fri, 02 Jan 2026 08
- CDT Equity announces 1-for-8 reverse stock split effective Oct 10 - Investing.com hu, 09 Oct 2025 07
- CDT’s $115M AI ‘signature’ bet reaches far beyond pharmaceuticals - Stock Titan Fri, 20 Feb 2026 08
- CDT Equity (CDT) lowers ELOC floor and issues $555,556 secured convertible note - Stock Titan Mon, 09 Mar 2026 20
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 10553 | 10975.0 | — | Stock Award(Grant) at price 1.04 per share. | FARLEY CHELE CHIAVACCI | Director | — | 2026-02-19 00:00:00 | D |
| 1 | 224800 | 402392.0 | — | Stock Award(Grant) at price 1.79 per share. | REGAN ANDREW J. | Chief Executive Officer | — | 2025-12-08 00:00:00 | I |
| 2 | 480000 | nan | — | — | BLIGH JAMES | Chief Financial Officer | — | 2025-09-19 00:00:00 | D |
| 3 | 1120000 | 768656.0 | — | Stock Award(Grant) at price 0.69 per share. | REGAN ANDREW J. | Chief Executive Officer | — | 2025-09-19 00:00:00 | D |
| 4 | 35000 | nan | — | — | LEWIS-HALL FREDA C | Director | — | 2025-08-12 00:00:00 | D |
| 5 | 35000 | nan | — | — | FARLEY CHELE CHIAVACCI | Director | — | 2025-08-12 00:00:00 | D |
| 6 | 35000 | nan | — | — | FRY SIMON JEREMY | Director | — | 2025-08-12 00:00:00 | D |
| 7 | 154799 | 500001.0 | — | Stock Award(Grant) at price 3.23 per share. | REGAN ANDREW J. | Chief Executive Officer | — | 2025-06-03 00:00:00 | I |
| 8 | 115194 | 100000.0 | — | Stock Award(Grant) at price 0.87 per share. | CHARLES FAITH L. | Director | — | 2025-04-16 00:00:00 | D |
| 9 | 47612 | 42375.0 | — | Stock Award(Grant) at price 0.89 per share. | LEWIS-HALL FREDA C | Director | — | 2025-03-28 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 1.45M | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.21 | 0.00 | 0.00 |
| NormalizedEBITDA | -15.35M | -3.85M | -3.42M | -2.76M |
| TotalUnusualItems | -500.00K | 6.90M | -1.46M | -411.00K |
| TotalUnusualItemsExcludingGoodwill | -500.00K | 6.90M | -1.46M | -411.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -17.80M | -535.00K | -4.89M | -3.66M |
| ReconciledDepreciation | 457.00K | 0.00 | ||
| EBITDA | -15.85M | 3.05M | -4.89M | -3.17M |
| EBIT | -16.31M | 3.05M | -4.89M | -3.17M |
| NetInterestIncome | -1.49M | -196.00K | 0.00 | |
| InterestExpense | 1.51M | 211.00K | 0.00 | |
| InterestIncome | 13.00K | 15.00K | 0.00 | |
| NormalizedIncome | -17.30M | -5.99M | -3.42M | -3.25M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -17.80M | -535.00K | -4.89M | -3.66M |
| TotalExpenses | 15.12M | 5.26M | 3.16M | 3.17M |
| TotalOperatingIncomeAsReported | -15.42M | -5.26M | -3.16M | -3.17M |
| DilutedAverageShares | 57.81K | 45.26K | 48.28K | 48.28K |
| BasicAverageShares | 57.81K | 44.65K | 48.28K | 48.28K |
| DilutedEPS | -307.95 | -1.07K | -101.23 | -75.75 |
| BasicEPS | -307.95 | -94.80 | -101.23 | -75.75 |
| DilutedNIAvailtoComStockholders | -17.80M | -6.06M | -4.89M | -3.66M |
| AverageDilutionEarnings | 0.00 | -5.52M | ||
| NetIncomeCommonStockholders | -17.80M | -535.00K | -4.89M | -3.66M |
| NetIncome | -17.80M | -535.00K | -4.89M | -3.66M |
| NetIncomeIncludingNoncontrollingInterests | -17.81M | 2.84M | -4.89M | -3.66M |
| NetIncomeContinuousOperations | -17.81M | 2.84M | -4.89M | -3.66M |
| PretaxIncome | -17.81M | 2.84M | -4.89M | -3.66M |
| OtherIncomeExpense | -1.20M | 8.30M | -1.73M | -484.00K |
| OtherNonOperatingIncomeExpenses | -700.00K | 1.40M | -265.00K | -73.00K |
| GainOnSaleOfSecurity | -500.00K | 6.90M | -1.46M | -411.00K |
| NetNonOperatingInterestIncomeExpense | -1.49M | -196.00K | 0.00 | |
| InterestExpenseNonOperating | 1.51M | 211.00K | 0.00 | |
| InterestIncomeNonOperating | 13.00K | 15.00K | 0.00 | |
| OperatingIncome | -15.12M | -5.26M | -3.16M | -3.17M |
| OperatingExpense | 15.12M | 5.26M | 3.16M | 3.17M |
| OtherTaxes | -300.00K | |||
| ResearchAndDevelopment | 3.38M | 90.00K | 111.00K | 283.00K |
| SellingGeneralAndAdministration | 12.04M | 5.17M | 3.05M | 2.89M |
| GeneralAndAdministrativeExpense | 12.04M | 5.17M | 3.05M | 2.89M |
| OtherGandA | 12.04M | 5.17M | 3.05M | 2.89M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 92.32K | 49.22K | 48.28K | 48.28K |
| ShareIssued | 92.32K | 49.22K | 48.28K | 48.28K |
| NetDebt | 6.68M | 2.01M | 749.00K | |
| TotalDebt | 7.46M | 985.00K | 2.01M | 749.00K |
| TangibleBookValue | -6.79M | -457.00K | -10.09M | -5.94M |
| InvestedCapital | 438.00K | 528.00K | -8.08M | -5.19M |
| WorkingCapital | -8.03M | 3.93M | -4.18M | |
| NetTangibleAssets | -6.79M | -457.00K | -10.09M | -5.94M |
| CapitalLeaseObligations | 226.00K | 0.00 | ||
| CommonStockEquity | -6.79M | -457.00K | -10.09M | -5.94M |
| TotalCapitalization | -6.79M | -457.00K | -8.25M | -5.19M |
| TotalEquityGrossMinorityInterest | -6.79M | -457.00K | -10.09M | -5.94M |
| StockholdersEquity | -6.79M | -457.00K | -10.09M | -5.94M |
| GainsLossesNotAffectingRetainedEarnings | 414.00K | 411.00K | 675.00K | -65.00K |
| OtherEquityAdjustments | 414.00K | 411.00K | 675.00K | -65.00K |
| RetainedEarnings | -29.10M | -11.30M | -10.77M | -5.88M |
| AdditionalPaidInCapital | 21.88M | 10.42M | 0.00 | |
| CapitalStock | 14.00K | 7.00K | 6.00K | 0.00 |
| CommonStock | 14.00K | 7.00K | 6.00K | 0.00 |
| PreferredStock | 0.00 | 0.00 | 0.00 | |
| TotalLiabilitiesNetMinorityInterest | 10.99M | 7.68M | 10.09M | 5.94M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 245.00K | 5.88M | 5.92M | 3.71M |
| DerivativeProductLiabilities | 138.00K | 142.00K | 0.00 | |
| TradeandOtherPayablesNonCurrent | 0.00 | 5.74M | 0.00 | |
| NonCurrentDeferredLiabilities | 0.00 | 4.08M | 2.96M | |
| NonCurrentDeferredRevenue | 0.00 | 4.08M | 2.96M | |
| LongTermDebtAndCapitalLeaseObligation | 107.00K | 0.00 | 1.83M | 749.00K |
| LongTermCapitalLeaseObligation | 107.00K | 0.00 | ||
| LongTermDebt | 1.83M | 749.00K | ||
| CurrentLiabilities | 10.74M | 1.80M | 4.18M | 2.23M |
| OtherCurrentLiabilities | 1.42M | 6.00K | ||
| CurrentDebtAndCapitalLeaseObligation | 7.35M | 985.00K | 175.00K | |
| CurrentCapitalLeaseObligation | 119.00K | 0.00 | ||
| CurrentDebt | 7.23M | 985.00K | 175.00K | |
| OtherCurrentBorrowings | 6.66M | 800.00K | 175.00K | |
| CurrentNotesPayable | 575.00K | 185.00K | ||
| PayablesAndAccruedExpenses | 3.39M | 816.00K | 2.58M | 2.23M |
| CurrentAccruedExpenses | 1.96M | 601.00K | 2.58M | 2.23M |
| Payables | 1.43M | 215.00K | ||
| AccountsPayable | 1.43M | 215.00K | 0.00 | |
| TotalAssets | 4.19M | 7.22M | 5.00K | 0.00 |
| TotalNonCurrentAssets | 1.48M | 1.49M | 5.00K | 0.00 |
| OtherNonCurrentAssets | 1.18M | 1.49M | ||
| GoodwillAndOtherIntangibleAssets | 0.00 | 5.00K | 0.00 | |
| OtherIntangibleAssets | 5.00K | |||
| NetPPE | 303.00K | 0.00 | ||
| GrossPPE | 303.00K | 0.00 | ||
| OtherProperties | 303.00K | |||
| CurrentAssets | 2.71M | 5.73M | 0.00 | |
| PrepaidAssets | 1.67M | 1.50M | 0.00 | |
| Receivables | 489.00K | 0.00 | ||
| OtherReceivables | 489.00K | |||
| CashCashEquivalentsAndShortTermInvestments | 554.00K | 4.23M | 0.00 | |
| CashAndCashEquivalents | 554.00K | 4.23M | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -9.73M | -7.72M | -2.27M | -2.15M |
| RepaymentOfDebt | -776.00K | 0.00 | ||
| IssuanceOfDebt | 3.23M | 2.29M | 1.11M | 688.00K |
| IssuanceOfCapitalStock | 3.33M | 0.00 | 1.34M | 1.21M |
| CapitalExpenditure | -51.00K | |||
| InterestPaidSupplementalData | 80.00K | 124.00K | 0.00 | |
| EndCashPosition | 554.00K | 4.23M | 0.00 | 0.00 |
| BeginningCashPosition | 4.23M | 0.00 | 0.00 | 252.00K |
| EffectOfExchangeRateChanges | -16.00K | 299.00K | 1.00K | 1.00K |
| ChangesInCash | -3.66M | 3.93M | -1.00K | -253.00K |
| FinancingCashFlow | 6.07M | 10.93M | 2.45M | 1.90M |
| CashFlowFromContinuingFinancingActivities | 6.07M | 10.93M | 2.45M | 1.90M |
| NetOtherFinancingCharges | 8.64M | |||
| ProceedsFromStockOptionExercised | 289.00K | 0.00 | ||
| NetCommonStockIssuance | 3.33M | 0.00 | 1.34M | 1.21M |
| CommonStockIssuance | 3.33M | 0.00 | 1.34M | 1.21M |
| NetIssuancePaymentsOfDebt | 2.45M | 2.29M | 1.11M | 688.00K |
| NetShortTermDebtIssuance | 2.45M | 2.29M | ||
| ShortTermDebtPayments | -776.00K | 0.00 | ||
| ShortTermDebtIssuance | 3.23M | 2.29M | ||
| NetLongTermDebtIssuance | 2.29M | 1.11M | 688.00K | |
| LongTermDebtIssuance | 2.29M | 1.11M | 688.00K | |
| InvestingCashFlow | -43.00K | 725.00K | -183.00K | 0.00 |
| CashFlowFromContinuingInvestingActivities | -43.00K | 725.00K | -183.00K | 0.00 |
| NetOtherInvestingChanges | 228.00K | -331.00K | ||
| NetInvestmentPurchaseAndSale | 8.00K | 497.00K | 148.00K | 0.00 |
| SaleOfInvestment | 498.00K | 497.00K | 148.00K | 0.00 |
| PurchaseOfInvestment | -490.00K | 0.00 | ||
| NetPPEPurchaseAndSale | -51.00K | 0.00 | ||
| PurchaseOfPPE | -51.00K | 0.00 | ||
| OperatingCashFlow | -9.68M | -7.72M | -2.27M | -2.15M |
| CashFlowFromContinuingOperatingActivities | -9.68M | -7.72M | -2.27M | -2.15M |
| ChangeInWorkingCapital | -142.00K | -2.52M | 596.00K | 1.36M |
| ChangeInOtherWorkingCapital | 331.00K | |||
| ChangeInOtherCurrentLiabilities | -124.00K | 0.00 | ||
| ChangeInOtherCurrentAssets | 0.00 | 5.00K | -5.00K | 0.00 |
| ChangeInPayablesAndAccruedExpense | 2.25M | -1.53M | 601.00K | 1.36M |
| ChangeInAccruedExpense | 1.03M | -1.75M | 601.00K | 1.36M |
| ChangeInPayable | 1.23M | 215.00K | ||
| ChangeInAccountPayable | 1.23M | 215.00K | 0.00 | |
| ChangeInPrepaidAssets | -2.27M | -990.00K | 0.00 | |
| OtherNonCashItems | 2.97M | 992.00K | 265.00K | |
| StockBasedCompensation | 1.63M | 199.00K | 0.00 | |
| ProvisionandWriteOffofAssets | 0.00 | -240.00K | 331.00K | |
| DepreciationAmortizationDepletion | 457.00K | 0.00 | ||
| DepreciationAndAmortization | 457.00K | 0.00 | ||
| AmortizationCashFlow | 447.00K | 0.00 | ||
| AmortizationOfIntangibles | 447.00K | 0.00 | ||
| Depreciation | 10.00K | 0.00 | ||
| OperatingGainsLosses | 3.20M | -5.62M | 1.43M | 149.00K |
| GainLossOnInvestmentSecurities | 2.48M | -5.60M | 1.43M | 149.00K |
| NetForeignCurrencyExchangeGainLoss | 13.00K | -39.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -17.80M | -535.00K | -4.89M | -3.66M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for CDT
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|